Residency · Residency · Chronic Pain Management

Peripheral Nerve Stimulation

Introduction

Peripheral nerve stimulation (PNS) is one of the oldest neuromodulation techniques, first applied clinically by Wall and Sweet in 1967. After decades of limited adoption -- held back by the need for open surgical placement and high complication rates -- PNS has experienced a renaissance driven by the development of percutaneous, minimally invasive leads and wireless, battery-free systems. These technological advances have expanded indications beyond traditional peripheral neuropathic pain to include headache disorders, post-surgical pain, and musculoskeletal conditions.

Historical Evolution

Open Surgical PNS (First Generation)

Early PNS required open surgical dissection to expose the target nerve and place a cuff or paddle electrode directly on it. Complication rates were high: nerve injury during dissection occurred in 2-5% of cases, lead migration in 20-40%, infection in 5-10%, and painful neuroma formation was a recognized risk. The long surgical recovery and significant morbidity limited widespread adoption, and the technique was reserved for severe, refractory peripheral neuropathic pain such as post-traumatic neuropathy and brachial plexus injury.

Percutaneous PNS (Second Generation)

The introduction of cylindrical percutaneous leads that could be placed adjacent to peripheral nerves under ultrasound or fluoroscopic guidance changed the landscape. No surgical exposure of the nerve was required, dramatically reducing perioperative morbidity. These leads are placed in the epineural or perineural space using a Tuohy needle or introducer, anchored subcutaneously, and connected to an external or implanted pulse generator.

Wireless and Battery-Free Systems (Third Generation)

The most recent generation of PNS systems eliminates the need for an IPG pocket entirely. Wireless systems (such as StimRouter, SPRINT PNS, and bioelectric signal therapy devices) use a small electrode implanted adjacent to the target nerve that receives power from an external transmitter worn on the skin. The 60-day temporary PNS systems (SPRINT) allow a prolonged stimulation trial with a percutaneous lead that is removed after the treatment period; a subset of patients experience sustained benefit even after the lead is explanted. This generation has dramatically reduced surgical complexity and the complication profile.

<image>Timeline illustration showing the evolution of peripheral nerve stimulation technology across three generations — first generation (1960s-1990s) showing an open surgical approach with nerve exposure and cuff electrode placement requiring general anesthesia, second generation (2000s-2010s) showing ultrasound-guided percutaneous lead placement adjacent to the peripheral nerve with connection to a subcutaneous IPG, and third generation (2010s-present) showing a wireless miniaturized electrode implanted percutaneously with an external wearable pulse transmitter providing power through the skin via radiofrequency coupling, each with labeled components and approximate dimensions</image>

Mechanism of Action

Peripheral Gate Control

PNS works by stimulating large-diameter A-beta afferent fibers within or adjacent to a peripheral nerve. Activation of these fibers modulates nociceptive input at the dorsal horn level through segmental inhibition -- the same gate control principle applied at the peripheral level rather than the dorsal columns. Orthodromic impulses travel to the dorsal horn and activate inhibitory interneurons. There is also additional modulation of peripheral nerve excitability and ectopic discharge at the nerve itself.

Peripheral Effects

At the nerve level, PNS reduces ectopic neural discharge from injured nerve segments, modulates neurogenic inflammation, may influence local blood flow and tissue healing, and promotes the release of endogenous analgesic substances at both the nerve and dorsal horn.

Central Plasticity

Sustained peripheral stimulation may induce central neuroplastic changes that outlast the stimulation period itself. This is the proposed mechanism for the residual analgesia observed after temporary PNS (the 60-day SPRINT system), where some patients continue to experience pain relief for weeks to months after the lead is removed. The idea is that prolonged normalization of afferent input can reverse maladaptive central sensitization.

Indications

Established Indications

Established indications for PNS include post-traumatic neuropathy with persistent neuropathic pain, post-surgical neuropathic pain from nerve injury during surgery (such as ilioinguinal neuralgia after hernia repair or intercostal neuralgia after thoracotomy), occipital neuralgia (stimulation of the greater and lesser occipital nerves), and CRPS when a specific peripheral nerve can be identified as the pain generator.

Emerging Indications

The list of emerging indications is growing. Chronic migraine is being treated with occipital nerve stimulation, sometimes combined with supraorbital stimulation. Chronic low back pain is being targeted through stimulation of the medial branch nerves or cluneal nerves. Knee osteoarthritis and post-arthroplasty pain are being addressed with femoral or saphenous nerve stimulation. Shoulder pain from post-surgical or rotator cuff pathology responds to axillary nerve stimulation. Combined occipital and supraorbital nerve stimulation is being investigated for cluster headache and hemicrania continua. Post-amputation pain is being treated by stimulating residual limb peripheral nerves for phantom limb pain.

Technique: Ultrasound-Guided Percutaneous PNS

General Approach

The procedure is performed under ultrasound guidance, with the target nerve identified in short-axis view. A Tuohy needle or specialized introducer is advanced to the perineural space under real-time imaging. The lead is deployed through the introducer with the electrode contacts positioned adjacent to the nerve -- not within it. Correct placement is confirmed by eliciting concordant paresthesia in the nerve's distribution at low stimulation amplitudes (0.1-0.5 mA).

Common Target Nerves and Approaches

The greater occipital nerve is targeted at the level of C1-C2, medial to the obliquus capitis inferior, or more distally at the nuchal line. The suprascapular nerve is approached in the suprascapular notch for shoulder pain. The lateral femoral cutaneous nerve is targeted at the inguinal ligament for meralgia paresthetica. The sciatic nerve can be approached in the proximal thigh or gluteal region for post-traumatic or post-surgical sciatic neuropathy. The tibial or peroneal nerve is accessed at the popliteal fossa or proximal leg for foot and ankle neuropathic pain. The median, ulnar, or radial nerves can be targeted in the forearm or upper arm for hand and wrist neuropathic pain.

<image>Ultrasound-guided percutaneous peripheral nerve stimulation placement illustration showing a short-axis sonographic view of the sciatic nerve in the proximal posterior thigh, with the hyperechoic honeycomb pattern of the nerve fascicles clearly visible between the biceps femoris and adductor magnus muscles, a Tuohy needle approaching from the lateral side with the tip positioned adjacent to the epineurium, and a percutaneous cylindrical lead being deployed through the needle with four electrode contacts positioned parallel to the nerve, alongside a schematic cross-section showing the ideal lead position in the perineural space without penetrating the epineurium</image>

Wireless and Temporary PNS Systems

SPRINT PNS System

The SPRINT system is a 60-day percutaneous PNS system designed for temporary implantation. A fine-wire lead (MicroLead) is placed percutaneously adjacent to the target nerve and connected to a small external pulse generator via a percutaneous connector. After 60 days, the lead is removed in the office by gentle traction. Studies have demonstrated sustained pain relief for weeks to months after lead removal in a subset of patients, with the proposed mechanism being reversal of maladaptive central plasticity during the stimulation period.

StimRouter System

The StimRouter is an implanted wireless electrode with no IPG. An external transmitter delivers power and programming via radiofrequency coupling through the skin. By eliminating the IPG pocket entirely, it avoids the complications associated with that component. It is indicated for chronic pain of peripheral nerve origin.

Bioelectric Signal Therapy

Emerging systems use waveforms designed to mimic endogenous bioelectric signals, with the aim of promoting tissue healing and nerve repair in addition to providing analgesia. These are currently under investigation in clinical trials.

Evidence Base

Occipital Nerve Stimulation for Chronic Migraine

The ONSTIM trial (Saper et al., 2011) was a randomized controlled trial that showed a 39% responder rate for occipital nerve stimulation compared to 6% for sham in chronic migraine. The larger multicenter PRISM study demonstrated moderate efficacy but was complicated by high lead migration rates. Occipital nerve stimulation remains an off-label application with variable insurance coverage.

PNS for Post-Amputation Pain

Gilmore et al. (2019) conducted an RCT of 60-day percutaneous PNS for post-amputation pain that demonstrated significant reduction in both residual and phantom limb pain, with benefits persisting 12 months after lead removal -- a striking finding that supports the central plasticity reversal hypothesis.

PNS for Musculoskeletal Pain

Emerging evidence supports PNS for chronic shoulder, knee, and low back pain. SPRINT studies have demonstrated efficacy for hemiplegic shoulder pain and chronic low back pain. This represents a potential paradigm shift: using PNS for nociceptive and mixed pain conditions, not only pure neuropathic pain.

Complications

Lead migration remains the most common complication, with rates varying by system from 2-25% depending on the technology used. Infection rates are lower with temporary systems and run 3-5% with permanent implants. Nerve injury is rare when ultrasound guidance and perineural (rather than intraneural) placement are used. Lead fracture was more common with older open surgical leads and is less frequent with modern percutaneous designs. Skin erosion at the lead exit site can occur with externalized temporary systems but is mitigated by proper anchoring and wound care. Allergic reactions to lead materials are uncommon.

<image>Anatomical diagram showing five common peripheral nerve stimulation target sites on a full anterior human body illustration — the greater occipital nerve at the occiput for headache, the suprascapular nerve at the shoulder for shoulder pain, the lateral femoral cutaneous nerve at the inguinal region for meralgia paresthetica, the sciatic nerve at the posterior thigh for lower extremity neuropathic pain, and the tibial nerve at the medial ankle for foot pain — each with a small inset showing the ultrasound appearance of the nerve with an adjacent PNS lead in cross-section</image>

Clinical Pearls

The renaissance of PNS is driven by minimally invasive technology; wireless and temporary systems have dramatically lowered the barrier to entry for both patients and physicians. Ultrasound guidance is essential for safe and accurate lead placement -- blind percutaneous PNS lead insertion should never be attempted. The concept of temporary PNS with sustained benefit after lead removal represents a unique therapeutic paradigm fundamentally different from SCS, where ongoing stimulation is required for ongoing benefit. For occipital neuralgia and chronic migraine, PNS may offer an alternative to repeated nerve blocks or ablation, though insurance coverage remains a practical challenge. PNS should be considered as a less invasive alternative to SCS for focal peripheral neuropathic pain, particularly when the pain is clearly attributable to a single peripheral nerve territory.

References

1. Deer TR, Esposito MF, McRoberts WP, et al. A systematic literature review of peripheral nerve stimulation therapies for the treatment of pain. Pain Med. 2020;21(8):1590-1603.
2. Gilmore CA, Ilfeld BM, Rosenow JM, et al. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial. Reg Anesth Pain Med. 2020;45(1):44-51.
3. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31(3):271-285.
4. Ilfeld BM, Plunkett A, Vijjeswarapu AM, et al. Percutaneous peripheral nerve stimulation (neuromodulation) for postoperative pain: A randomized, sham-controlled pilot study. Anesthesiology. 2021;135(1):95-110.

Read this lecture as Markdown